O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+17.87%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.42B
AUM Growth
+$5.42B
(+22%)
Cap. Flow
+$335M
Cap. Flow
% of AUM
6.18%
Top 10 Holdings %
Top 10 Hldgs %
41.42%
Holding
137
New
14
Increased
37
Reduced
30
Closed
15
Top Buys
| 1 |
Merck
MRK
|
$92.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$87.1M |
| 3 |
SHPG
Shire pic
SHPG
|
$82.8M |
| 4 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
$51.7M |
| 5 |
Exelixis
EXEL
|
$50.9M |
Top Sells
| 1 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
$102M |
| 2 |
Incyte
INCY
|
$43.2M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$26.9M |
| 4 |
MAKO
MAKO SURGICAL CORP COM
MAKO
|
$26.7M |
| 5 |
ANTH
Anthera Pharmaceuticals, Inc.
ANTH
|
$26.3M |
Sector Composition
| 1 | Healthcare | 86.37% |
| 2 | Financials | 1.83% |
| 3 | Technology | 0.15% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $300M | 5.36% | 4,777,800 -44,000 | -0.9% | -$2.77M |
|
2
Amgen
AMGN
$155B
| $294M | 5.25% | 2,629,600 +10,200 | +0.4% | +$1.14M |
|
|
3
Merck
MRK
$210B
| $289M | 5.16% | 6,076,000 +1,950,600 | +47% | +$92.9M |
|
4
Biogen
BIIB
$19.4B
| $247M | 4.41% | 1,026,400 +600 | +0.1% | +$144K |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $241M | 4.3% | 5,204,000 +1,882,000 | +57% | +$87.1M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $201M | 3.59% | 1,307,000 +70,600 | +6% | +$10.9M |
|
7
Viatris
VTRS
$12.3B
| $193M | 3.44% | 5,049,000 +62,000 | +1% | +$2.37M |
|
|
8
Incyte
INCY
$16.5B
| $171M | 3.05% | 4,473,000 -1,133,000 | -20% | -$43.2M |
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $161M | 2.86% | 513,100 +162,000 | +46% | +$50.7M |
|
|
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $149M | 2.65% | 2,151,607 +973 | +0% | +$67.2K |
|
11
Thermo Fisher Scientific
TMO
$186B
| $142M | 2.54% | 1,546,000 -240,000 | -13% | -$22.1M |
|
|
MDVN
12
DELISTED
MEDIVATION, INC.
MDVN
| $137M | 2.44% | 2,284,500 +812,400 | +55% | +$48.7M |
|
13
HCA Healthcare
HCA
$94.5B
| $131M | 2.33% | 3,053,000 -313,300 | -9% | -$13.4M |
|
14
Illumina
ILMN
$15.8B
| $129M | 2.3% | 1,593,800 -58,000 | -4% | -$4.69M |
|
15
Pfizer
PFE
$141B
| $115M | 2.06% | 4,010,400 -892,900 | -18% | -$25.6M |
|
16
Agilent Technologies
A
$35.7B
| $115M | 2.05% | 2,246,000 +392,000 | +21% | +$20.1M |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $114M | 2.04% | 1,581,700 +240,500 | +18% | +$17.4M |
|
|
ESRX
18
DELISTED
Express Scripts Holding Company
ESRX
| $110M | 1.97% | 1,783,000 -124,170 | -7% | -$7.67M |
|
19
Insulet
PODD
$23.9B
| $103M | 1.84% | 2,852,500 -196,000 | -6% | -$7.1M |
|
20
Elevance Health
ELV
$71.8B
| $101M | 1.8% | 1,206,000 +19,000 | +2% | +$1.59M |
|
|
AET
21
DELISTED
Aetna Inc
AET
| $99.4M | 1.77% | 1,553,000 +34,000 | +2% | +$2.18M |
|
22
UnitedHealth
UNH
$281B
| $95.2M | 1.7% | 1,329,000 +121,000 | +10% | +$8.66M |
|
|
SHPG
23
DELISTED
Shire pic
SHPG
| $82.8M | 1.48% | +690,900 | New | +$82.8M |
|
|
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $80M | 1.43% | 4,592,600 +71,800 | +2% | +$1.25M |
|
25
AbbVie
ABBV
$372B
| $77.9M | 1.39% | 1,742,000 -35,000 | -2% | -$1.57M |
|